A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis
Abstract Background In recent years, new treatment options for chronic lymphocytic leukemia (CLL) have shown great potential. In China, the large CLL patient base translates into considerable clinical and economic burden, factors such as cost-effectiveness will be of significant importance in guidin...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2026-01-01
|
| Ráidu: | Cost Effectiveness and Resource Allocation |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s12962-025-00705-w |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|